Sheraton Boston Hotel | Acute myeloid leukemia (AML) remains one of the most challenging hematologic malignancies, with rising incidence globally and persistently poor outcomes despite advances in targeted agents and combination regimens. Relapse and disease progression remain common, particularly in older and high-risk patients, reinforcing the urgent need for new therapeutic approaches capable of delivering durable benefit.
At the 2026 IO360 Summit, Alloplex Biotherapeutics’ CEO and Scientific Founder, Dr. Frank Borriello, MD, PhD, will present new pre-clinical data extending the potential applicability of the company’s ENLIST immune cell training platform to AML. ENLIST is an ex vivo process designed to activate peripheral blood mononuclear cells (PBMCs) in a way that enhances both cytolytic activity and antigen-presenting cell (APC) function, producing SUPLEXA cells with a hybrid immune phenotype and broad anti-tumor activity.
In this presentation, Dr. Borriello will describe preliminary studies demonstrating that SUPLEXA cells can be efficiently generated from commercially sourced AML whole blood–derived PBMCs, even when leukemic blasts constitute a large proportion of the starting material. Despite advanced disease features and cytogenetic abnormalities within the myeloid compartment, the resulting SUPLEXA cells were phenotypically indistinguishable from those derived from normal donors. These findings suggest that a sufficient pool of functional lymphoid cells persists in advanced AML patients to support a non-engineered, autologous cell therapy approach.
The data build on observations from Alloplex’s completed Phase 1 clinical trial in solid tumors, where SUPLEXA cells demonstrated a pristine safety profile and evidence of single-agent antitumor activity. Notably, pharmacodynamic findings from that study suggested bone marrow trafficking and modulation of myeloid-derived suppressor cells, supporting the hypothesis that SUPLEXA cells may act directly within the bone marrow niche.
Together, these pre-clinical findings and prior clinical experience inform the rationale for advancing SUPLEXA cells toward clinical evaluation in AML, in combination with existing standards of care, and are expected to support a future IND submission.
IO360 attendees are invited to join this session and engage in discussion around the implications of these data for AML treatment, immune cell platform development, and partnering opportunities.
Those interested in meeting with Dr. Borriello during the Summit are encouraged to connect via the IO360 partnering system or reach out to the Alloplex team in advance.